Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 89

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 89
---
,311 will be recognized in the business combination. The Company expects to apply cash and cash equivalents derived from the Business Combinations to partially settle estimated transaction costs and cancel the remaining balance through other sources of financing considering the available credit lines (according to the table above, the excess of estimated transaction costs over cash sources amounts to $366,126). Certain United States Federal Income Tax Considerations For a discussion summarizing the material United States federal income tax considerations of an exercise of Redemption Rights, please see “ Material U.S. Federal Income Tax Considerations” below. Accounting Treatment of the Business Combination OmnigenicsAI will account for the Business Combination as a capital reorganization in accordance with IFRS as issued by the IASB. Under this method of accounting, APx will be treated as the “acquired” company for financial reporting purposes and OmngenicsAI will be the accounting “acquirer.” This determination was primarily based on the assumptions that OmngenicsAI’s shareholders will hold a majority of the voting power of the Combined Company, the Combined Company’s operations will substantially comprise the ongoing operations of OmngenicsAI, OmngenicsAI’s designees are expected to comprise a majority of the governing body of the Combined Company, and OmngenicsAI’s senior management will comprise the senior management of the Combined Company. APx does not meet the definition of a “business” pursuant to IFRS3, Business Combinations, and thus, for accounting purposes, OmnigenicsAI will account for the Business Combination as a capital reorganization. The net assets of APx will be stated at historical cost, with no goodwill or other intangible assets recorded. The Business Combination will be accounted for within the scope of IFRS 2 — Share -basedPayments (“IFRS 2”). As a result, any excess of fair value of the Company Shares issued over the fair value of APx’s identifiable net assets acquired, represent compensation for the service in respect of a stock exchange listing for the Company Shares and is expensed upon consummation. For a discussion summarizing the anticipated accounting treatment of the Business Combination, please see “ Anticipated Accounting Treatment of the Business Combination.” APx Board of Directors’ Reasons for the Approval of the Business Combination The APx Board unanimously approved the Business Combination after consulting with APx’s management and advisors and conducting a comprehensive review of due diligence findings. The APx Board evaluated various factors, including the Company’s competitive position in the healthcare space, combining advanced genomics, microbiome analysis,